This is a fast-moving regulatory area, so I want to be straightforward with you: What Happened The FDA declared the semaglutide shortage over in early 2025, which restricted most compounding pharmacies from making compounded semaglutide (Ozempic/Wegovy). Tirzepatide (Mounjaro/Zepbound) followed similarly. Services Still Navigating This Space Hims & Hers - Fought back legally and continued offering compounded semaglutide for a period, though their status has shifted with ongoing legal battles. Nuvation/Mochi Health - Has worked with compounding partners and personalized dosing formulations. Ivy RX - Focused on compounded options with add-ins (like B12) that may fall under different rules. Important Caveats Status changes frequently - what's available this week may not be next week Some services use 503A vs 503B pharmacies, which have different rules "Personalized" compounds with additives occupy a legal gray area Prices and availability vary significantly by state My Honest Recommendation Check directly with the service today and ask specifically about their current legal status and pharmacy sourcing. Also consider whether brand-name options with manufacturer coupons (Lilly's savings program, etc.) might be comparable in cost. Would you like help comparing brand-name access options instead?
Mentioned in position 4 of 4
Read full answer with sources →